Concept paper on development and lifecycle of personalised medicines and companion diagnostics By Anna Jurczynska | August 3, 2017 Posted in Recent News and tagged companion diagnostics, ema, European Medicines Agency, personalised medicines ← FDA Working to Lift Barriers to Generic Drug CompetitionEMA and the pharmaceutical industry →